Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,019 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.
Rinnerthaler G, Egle D, Bartsch R, Schmitt CA, Petzer A, Balic M, Petru E, Denison U, Singer CF, Bjelic-Radisic V, Gampenrieder SP, Knauer M, Sotlar K, Brunner C, Posch F, Hlauschek D, Sölkner L, Bago-Horvath Z, Filipits M, Gili M, Ritter M, Wieser V, Albertini C, Zaborsky N, Weiss L, Marhold M, Schneeweiss B, Pusch R, Gnant M, Greil R. Rinnerthaler G, et al. Among authors: singer cf. Nat Cancer. 2025 Jan 16. doi: 10.1038/s43018-024-00890-2. Online ahead of print. Nat Cancer. 2025. PMID: 39820125
Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment.
Wu CY, Kupferschmid AC, Chen L, McManus AJ, Kivisäkk P, Galler JA, Schwab NA, DesRuisseaux LA, Williams VJ, Gerber J, Riley M, Young C, Guzmán-Vélez E, Dodge HH, Tanzi RE, Singer CM, Arnold SE. Wu CY, et al. Among authors: singer cm. Alzheimers Dement (N Y). 2025 Jan 15;11(1):e70023. doi: 10.1002/trc2.70023. eCollection 2025 Jan-Mar. Alzheimers Dement (N Y). 2025. PMID: 39817194 Free PMC article.
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, D'Hondt V, Conlin AK, Guarneri V, Wapnir IL, Jackisch C, Arce-Salinas C, Fasching PA, DiGiovanna MP, Crown JP, Wuelfing P, Shao Z, Rota Caremoli E, Bonnefoi HR, Hennessy BT, Stamatovic L, Castro-Salguero H, Brufsky AM, Knott A, Siddiqui A, Lambertini C, Boulet T, Nyawira B, Restuccia E, Loibl S; KATHERINE Study Group. Geyer CE Jr, et al. N Engl J Med. 2025 Jan 16;392(3):249-257. doi: 10.1056/NEJMoa2406070. N Engl J Med. 2025. PMID: 39813643 Clinical Trial.
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.
Singer CF, Jahn SW, Hlauschek D, Heber UM, Mang-Manger C, Egle D, Balic M, Pichler A, Pfeiler G, Kacerovsky-Strobl S, Suppan C, Ritter M, Petru E, Greil R, Bago-Horvath Z, Deutschmann C, Steger GG, Seifert M, Fitzal F, Bartsch R, Santhanagopal A, Machacek-Link J, Sellami D, Schwarz M, Fesl C, Sölkner L, Esker S, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Singer CF, et al. Cancer Commun (Lond). 2025 Jan 6. doi: 10.1002/cac2.12657. Online ahead of print. Cancer Commun (Lond). 2025. PMID: 39757921 No abstract available.
The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation.
Katona BW, Lubinski J, Pal T, Huzarski T, Foulkes WD, Moller P, Eisen A, Randall Armel S, Neuhausen SL, Raj R, Aeilts A, Singer CF, Bordeleau L, Karlan B, Olopade O, Tung N, Zakalik D, Kotsopoulos J, Fruscio R, Eng C, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Katona BW, et al. Among authors: singer cf. Cancer. 2025 Jan 1;131(1):e35666. doi: 10.1002/cncr.35666. Epub 2024 Nov 29. Cancer. 2025. PMID: 39611336 Free PMC article.
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study.
Montagna G, Laws A, Ferrucci M, Mrdutt MM, Sun SX, Bademler S, Balbaloglu H, Balint-Lahat N, Banys-Paluchowski M, Barrio AV, Benson J, Bese N, Boughey JC, Boyle MK, Diego EJ, Eden C, Eller R, Goldschmidt M, Hlavin C, Heidinger M, Jelinska J, Karadeniz Cakmak G, Kesmodel SB, King TA, Kuerer HM, Loesch J, Milardi F, Murawa D, Moo TA, Menes TS, Passeri D, Pastoriza JM, Perhavec A, Pislar N, Polidorio N, Rami A, Ryu JM, Schulz A, Sevilimedu V, Ugurlu MU, Uras C, van Hemert A, Wong SM, Yoo TR, Zhang JQ, Karanlik H, Cabioğlu N, Peeters MV, Morrow M, Weber WP; ICARO Study Group. Montagna G, et al. J Clin Oncol. 2024 Nov 7:JCO2401052. doi: 10.1200/JCO.24.01052. Online ahead of print. J Clin Oncol. 2024. PMID: 39509672
1,019 results